Navigation Links
Nocebo: Induced to be ill
Date:7/12/2012

Negative suggestion can induce symptoms of illness. Nocebo effects are the adverse events that occur during sham treatment and/or as a result of negative expectations. While the positive counterpartthe placebo effecthas been intensively studied in recent years, the scientific literature contains few studies on nocebo phenomena. In the latest issue of Deutsches rzteblatt International, Winfried Huser of the Technical University of Munich and his co-authors present the underlying neurobiological mechanisms and highlight the relevance of the nocebo effect in everyday clinical practice (Dtsch Arztebl Int 2012; 109(26) 459).

Nocebo responses can, for instance, be brought about by unintended negative suggestion on the part of doctors or nurses, e.g., when informing the patient about the possible complications of a proposed treatment. It is also assumed that a certain proportion of the undesired effects of drugs can be attributed to nocebo effects. The mechanisms behind this phenomenon areas with placebo effectslearning by Pavlovian conditioning and reaction to induced expectations.

What are the consequences for clinical practice? Doctors find themselves in an ethical dilemma between their obligation to tell the patient about the possible side effects of a treatment and their duty to minimize the risk of a medical intervention and thus to avoid triggering nocebo effects. As one possible strategy to solve this dilemma, Huser et al. suggest emphasizing the tolerability of therapeutic measures. Another option, with the patient's permission, would be to desist from discussing undesired effects during the patient briefing.


'/>"/>
Contact: PD Dr. med. Winfried Huser
whaeuser@klinikum-saarbruecken.de
Deutsches Aerzteblatt International
Source:Eurekalert

Page: 1

Related medicine news :

1. Columbus Allergist Dr. Summit Shah Discusses Recent Findings on Food Allergies and Exercise-Induced Anaphylaxis
2. Induced Labor Late in Pregnancy Has Pros, Cons
3. Risk of CT-induced cancer minimal compared to risk of dying from disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... Hamden, CT (PRWEB) , ... December 07, 2016 , ... ... has prompted an outpouring of comments on social media that offer a rare glimpse ... adult psychiatrist, leading ADHD authority and New York Times bestselling author, has described people ...
(Date:12/7/2016)... ... 2016 , ... They are musicians and librarians, fashion designers and fitness instructors, ... New England and around the nation. What do they have in common? All have ... beautiful and compelling new photographic exhibit debuting Friday, December 9 at Logan International Airport ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... is now promoting to the US market its advanced highly customizable contact technology ... and ODU TURNTAC®. These advanced technologies are ideal for a wide range of ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... consultation services to residents in the Sacramento/Folsom region, is initiating a charity event ... , The Another Choice Another Chance treatment center in Sacramento works to provide ...
(Date:12/7/2016)... PA (PRWEB) , ... December 07, 2016 , ... One ... regular changing of the securement tape is painful for her. "This is why the ... to patients’ heads," she said. , They then created a prototype of the patent-pending ...
Breaking Medicine News(10 mins):
(Date:12/6/2016)... VILLAGE, Calif. , Dec. 6, 2016 ... privately held, clinical-stage medical dermatology and aesthetics ... plc, a privately held specialty pharmaceutical company ... common inflammatory skin conditions, including psoriasis, atopic ... of the agreement, Sienna will make an ...
(Date:12/6/2016)... , Dec. 6, 2016  Arcturus Therapeutics, Inc. ... company, announced today that it entered into collaboration ... therapeutics for the treatment of NASH and other ... delivery platform LUNAR™ and UNA Oligomer chemistry. The ... Takeda,s long-standing commitment to and expertise in GI ...
(Date:12/6/2016)... , Dec. 6, 2016  Regulus Therapeutics Inc. ... leading the discovery and development of innovative medicines ... candidates at its R&D day, held in ... RGLS5040, is an anti-miR targeting microRNA-27 (miR-27) for ... RGLS4326, is an anti-miR targeting microRNA-17 (miR-17) for ...
Breaking Medicine Technology: